STI-571 |
4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-methanesulfonate-benzamide |
(CAS 220127-57-1) |
|
Description: |
Imatinib (mesylate) is a first generation tyrosine kinase inhibitor that is used in the treatment of chronic myelogenous leukemia (CML), gastrointestinal stromal tumors (GIST), and other cancers. It selectively targets certain tyrosine kinases, including c-ABL, platelet-derived growth factor receptor, and KIT. In CML, imatinib (mesylate) inhibits the oncoprotein BCR-ABL, the product of the Philadelphia chromosome gene fusion. |
Product No. |
KT20003 |
Product Name |
STI-571 |
Synonyms |
Gleevec; Glivec; CGP-57148B;Imatinib Mesylate |
Formal Name |
4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-methanesulfonate-benzamide |
CAS Number |
220127-57-1 |
Molecular Formula |
C29H31N7O · CH4SO3 |
Formula Weight |
589.7 |
Formulation |
A crystalline solid |
Purity |
98%min |
Stability |
1 year |
Storage |
-20°C |
Shipping |
USD45 for Europe and USA. No shipping charge once amount reach USD500. |
Quality Control |
HNMR,CNMR,LCMS,HPLC,IR,etc. |
Price & Availability |
In Stock. Price Negotiated. |
|
Related Products: |
AC710
AC710 Mesylate
Amuvatinib
AZD2932
BIBF 1120
Bosutinib
BAY-43-9006
Axitinib |
|